IGF2BP1 and neoplasm: The activation of the MIF - (CD74+CXCR4) axis indicates that IGF2BP1-overexpressing tumor cells may facilitate immune evasion through this pathway, consequently undermining anti-tumor immune responses and adversely impacting patient prognosis in immunotherapy contexts.